Ignite Creation Date:
2025-12-24 @ 11:34 PM
Ignite Modification Date:
2026-01-03 @ 11:52 PM
Study NCT ID:
NCT02340156
Status:
TERMINATED
Last Update Posted:
2021-03-03
First Post:
2014-12-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
Sponsor:
SynerGene Therapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-12
Start Date Type:
None
Primary Completion Date:
2018-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-11
Completion Date Type:
ACTUAL
First Submit Date:
2014-12-18
First Submit QC Date:
None
Study First Post Date:
2015-01-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-11-06
Results First Submit QC Date:
None
Results First Post Date:
2021-03-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-02-11
Last Update Post Date:
2021-03-03
Last Update Post Date Type:
ACTUAL